Boston Scientific (NYSE:BSX) experienced a 6% decline in stock price over the last quarter, amid a period of market uncertainty driven by new tariffs imposed by the U.S. and retaliatory measures from ...

The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.6% annually through 2032, ...

Despite a shaky quarter due to U.S.-China trade tensions and a 6% dip in stock price, Boston Scientific still flexed its ...

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance cardiac cryoablation system in treating ...

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Boston Scientific (BSX – Research Report).

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.